Experimental modelEffect of Whole Bone Marrow Cell Infusion in the Progression of Experimental Chronic Renal Failure
Section snippets
Materials and Methods
Animal procedures were performed in accordance with protocols approved by our Animal Care and Use Committee. Fifteen adult male Wistar rats (250 to 300 g) underwent 5/6 renal mass reduction as previously described.3 Renal function was assessed by measurements of serum creatinine (sCr), creatinine clearance (Clcr), and 24-hour proteinuria at baseline, as well as 60 and 120 days after surgery. Bone marrow cells isolated from femoral and tibial bones of Wistar rats were separated into mononuclear
Results
sCr at baseline was 0.43 ± 0.04 mg/dL in the control group, 0.43 ± 0.05 mg/dL in the MoSC group, and 0.5 ± 0.1 mg/dL in the MSC group (Table 1). At 120 days, sCr values were 1.31 ± 0.5 mg/dL (control), 0.81 ± 0.2 mg/dL (MoSC), and 0.95 ± 0.1 mg/dL (MSC) (P = NS). The percentages of increase in sCr at day 120 versus the baseline levels were: 205% (control), 81% (MoSC), and 97.5% (MSC). Baseline values of Clcr did not vary significantly among the groups (control = 1.23 ± 0.33 mL/min; MoSC = 1.14
Discussion
Stem cell therapy has been used to repair injuries in liver, heart, and brain models. Reports have shown that bone marrow stem cells contribute to the repair of acutely damaged kidneys.7 Our results showed that injection of MoSCs or MSCs may have an effect on the CRF induced in rats because after 120 days treated animals showed a increase in sCr at least two times lower than untreated rats. In addition, the rate of progression of CRF, measured by the decline in Clcr, was significantly reduced
References (7)
- et al.
Multipotent mesenchymal stem cells reduce interstitial fibrosis but do not delay progression of chronic kidney disease in collagen4A3-deficient mice
Kidney Int
(2006) - et al.
Minimal criteria for defining multipotent mesenchymal stromal cellsThe International Society for Cellular Therapy position statement
Cytotherapy
(2006) Stem cell approaches for the treatment of renal failure
Pharmacol Rev
(2005)
Cited by (0)
This work was supported in part by the FAMERP-BAP/FUNFARME and Braile Biomédica.